Circulating sphingolipid biomarkers in models of type 1 diabetes

Journal of Lipid Research

Volumn 52, Issue 3, 2011, Pages 509-517

  Fox, Todd E ^a   Bewley, Maria C ^a   Unrath, Kellee A ^a   Pedersen, Michelle M ^a   Anderson, Robert E ^b   Jung, Dae Young ^a   Jefferson, Leonard S ^a   Kim, Jason K ^a   Bronson, Sarah K ^a   Flanagan, John M ^a   Kester, Mark ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Ceramide; Lipidomics; Nervonic acid; Sphingomyelin cerebrosides; Sphingosine 1 phosphate

Indexed keywords

15 TETRACOSENOIC ACID; BIOLOGICAL MARKER; CERAMIDE; CEREBROSIDE; FATTY ACID; INSULIN; OMEGA 9 FATTY ACID; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE MARKER; DRUG TARGETING; FATTY ACID BLOOD LEVEL; HEART; INSULIN DEPENDENT DIABETES MELLITUS; LIPID DIET; LIVER; MALE; MOUSE; NONHUMAN; NUTRITION; PRIORITY JOURNAL; RAT; STRESS;

ALLELES; ANIMALS; BIOLOGICAL MARKERS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FATTY ACIDS; FEMALE; INSULIN; LIVER; LYSOPHOSPHOLIPIDS; MALE; MICE; MUTATION; MYOCARDIUM; RATS; SPHINGOLIPIDS; SPHINGOSINE;

EID: 79953232027     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M010595     Document Type: Article

References (28)

1. Fox, T. E., and M. Kester. 2010. Therapeutic strategies for diabetes and complications:a role for sphingolipids? Adv. Exp. Med. Biol. 688:206-216.
2. Holland, W. L., J. T. Brozinick, L. P. Wang, E. D. Hawkins, K. M. Sargent, Y. Liu, K. Narra, K. L. Hoehn, T. A. Knotts, A. Siesky, et al. 2007. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5: 167-179.
3. Aerts, J. M., R. Ottenhoff, A. S. Powlson, A. Grefhorst, M. van Eijk, P. F. Dubbelhuis, J. Aten, F. Kuipers, M. J. Serlie, T. Wennekes, et al. 2007. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes. 56:1341-1349. (Pubitemid 46715620)
4. Zhao, H., M. Przybylska, I. H. Wu, J. Zhang, C. Siegel, S. Komarnitsky, N. S. Yew, and S. H. Cheng. 2007. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes. 56:1210-1218.
5. Hong, E. G., D. Y. Jung, H. J. Ko, Z. Zhang, Z. Ma, J. Y. Jun, J. H. Kim, A. D. Sumner, T. C. Vary, T. W. Gardner, et al. 2007. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling. Am. J. Physiol. Endocrinol. Metab. 293:E1687-E1696.
6. Fox, T. E., X. Han, S. Kelly, A. H. Merrill 2nd, R. E. Martin, R. E. Anderson, T. W. Gardner, and M. Kester. 2006. Diabetes alters sphingolipid metabolism in the retina:a potential mechanism of cell death in diabetic retinopathy. Diabetes. 55:3573-3580.
7. Merrill, A. H., Jr., M. C. Sullards, J. C. Allegood, S. Kelly, and E. Wang. 2005. Sphingolipidomics:high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods. 36:207-224.
8. Wijesinghe, D. S., J. C. Allegood, L. B. Gentile, T. E. Fox, M. Kester, and C. E. Chalfant. 2010. Use of high performance liquid chromatography- electrospray ionization-tandem mass spectrometry for the analysis of ceramide-1-phosphate levels. J. Lipid Res. 51:641-651.
9. Martin, R. E., M. H. Elliott, R. S. Brush, and R. E. Anderson. 2005. Detailed characterization of the lipid composition of detergent-resistant membranes from photoreceptor rod outer segment membranes. Invest. Ophthalmol. Vis. Sci. 46:1147-1154.
10. Zeidan, Y. H., and Y. A. Hannun. 2007. Translational aspects of sphingolipid metabolism. Trends Mol. Med. 13:327-336.
11. Yoshioka, M., T. Kayo, T. Ikeda, and A. Koizumi. 1997. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes. 46:887-894. (Pubitemid 27188269)
12. Brunengraber, D. Z., B. J. McCabe, T. Kasumov, J. C. Alexander, V. Chandramouli, and S. F. Previs. 2003. Influence of diet on the modeling of adipose tissue triglycerides during growth. Am. J. Physiol. Endocrinol. Metab. 285:E917-E925.
13. Kim, J. K., H. J. Kim, S. Y. Park, A. Cederberg, R. Westergren, D. Nilsson, T. Higashimori, Y. R. Cho, Z. X. Liu, J. Dong, et al. 2005. Adipocyte-specific overexpression of FOXC2 prevents diet-induced increases in intramuscular fatty acyl CoA and insulin resistance. Diabetes. 54:1657-1663. (Pubitemid 40770755)
14. Weisberg, S. P., D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante, Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112:1796-1808.
15. Xu, H., G. T. Barnes, Q. Yang, G. Tan, D. Yang, C. J. Chou, J. Sole, A. Nichols, J. S. Ross, L. A. Tartaglia, et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112:1821-1830.
16. Deutschman, D. H., J. S. Carstens, R. L. Klepper, W. S. Smith, M. T. Page, T. R. Young, L. A. Gleason, N. Nakajima, and R. A. Sabbadini. 2003. Predicting obstructive coronary artery disease with serum sphingosine-1- phosphate. Am. Heart J. 146:62-68.
17. Oda, E., K. Hatada, J. Kimura, Y. Aizawa, P. V. Thanikachalam, and K. Watanabe. 2005. Relationships between serum unsaturated fatty acids and coronary risk factors:negative relations between nervonic acid and obesity-related risk factors. Int. Heart J. 46:975-985.
18. Wang, L., X. P. Xing, A. Holmes, C. Wadham, J. R. Gamble, M. A. Vadas, and P. Xia. 2005. Activation of the sphingosine kinase-signaling pathway by high glucose mediates the proinflammatory phenotype of endothelial cells. Circ. Res. 97:891-899.
19. Ma, M. M., J. L. Chen, G. G. Wang, H. Wang, Y. Lu, J. F. Li, J. Yi, Y. J. Yuan, Q. W. Zhang, J. Mi, et al. 2007. Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice. Diabetologia. 50:891-900. (Pubitemid 46355826)
20. Whetzel, A. M., D. T. Bolick, S. Srinivasan, T. L. Macdonald, M. A. Morris, K. Ley, and C. C. Hedrick. 2006. Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ. Res. 99:731-739.
21. Means, C. K., C. Y. Xiao, Z. Li, T. Zhang, J. H. Omens, I. Ishii, J. Chun, and J. H. Brown. 2007. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 292:H2944-H2951.
22. Sanna, M. G., J. Liao, E. Jo, C. Alfonso, M. Y. Ahn, M. S. Peterson, B. Webb, S. Lefebvre, J. Chun, N. Gray, et al. 2004. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem. 279: 13839-13848.
23. Forrest, M., S. Y. Sun, R. Hajdu, J. Bergstrom, D. Card, G. Doherty, J. Hale, C. Keohane, C. Meyers, J. Milligan, et al. 2004. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J. Pharmacol. Exp. Ther. 309:758-768.
24. Budde, K., R. L. Schmouder, R. Brunkhorst, B. Nashan, P. W. Lucker, T. Mayer, S. Choudhury, A. Skerjanec, G. Kraus, and H. H. Neumayer. 2002. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13:1073-1083.
25. Wang, Y., D. Botolin, J. Xu, B. Christian, E. Mitchell, B. Jayaprakasam, M. G. Nair, J. M. Peters, J. V. Busik, L. K. Olson, et al. 2006. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J. Lipid Res. 47:2028-2041. (Pubitemid 44401991)
26. Sargent, J. R., K. Coupland, and R. Wilson. 1994. Nervonic acid and demyelinating disease. Med. Hypotheses. 42:237-242.
27. Sharma, K. R., J. Cross, O. Farronay, D. R. Ayyar, R. T. Shebert, and W. G. Bradley. 2002. Demyelinating neuropathy in diabetes mellitus. Arch. Neurol. 59:758-765.
28. Zador, I. Z., G. D. Deshmukh, R. Kunkel, K. Johnson, N. S. Radin, and J. A. Shayman. 1993. A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus. J. Clin. Invest. 91:797-803.